DLA-DQB1 alleles and bone marrow transplantation experiments in narcoleptic dogs.

Human narcolepsy is a neurological disorder known to be tightly associated with HLA-DQB1*0602. A clinically similar disorder has been described in various dog breeds. The canine form of the disease is inherited as an autosomal recessive disorder in Labrador retrievers and Doberman pinschers (canarc-1) but occurs sporadically in other breeds, most typically dachshunds and poodles. In this study, we have examined if there is a relationship between the development of narcolepsy and specific dog leukocyte antigen (DLA)-DQB1 alleles. Ninety-nine dogs were typed for DLA-DQB1-31 with narcolepsy and 68 control animals. Recent studies have linked the development of autosomal recessive canine narcolepsy to a disruption of the hypocretin receptor 2 (Hcrtr2) gene on the same chromosome as the canine MHC region (CFA12), but not close to the DLA. Four Hcrtr2-positive families (two Doberman pinscher families, one Labrador retriever family, one dachshund family) were analyzed at the DLA-DQ level. No relationship was found between narcolepsy and DLA in Hcrtr2-mediated narcolepsy but loose genetic linkage was observed (Zmax=2.3 at theta=25%, m= 40). Bone marrow transplantation between two DLA identical affected (Hcrtr2-/-) and unaffected (Hcrtr2+/-) siblings was also performed and found not to be successful neither in transmitting narcolepsy nor in relieving the symptoms in Doberman pinschers. DLA-DQB1 was next studied in 11 dogs with sporadic (non-familial) narcolepsy and in unrelated control animals of the same and different breeds. The allelic and carrier frequencies of various DLA-DQB1 alleles were analyzed. There was no strong positive or negative correlation between the development of narcolepsy and specific DLA-DQB1 alleles. These results do not support the involvement of DLA-DQ in canine narcolepsy, whether of sporadic or familial origin.

[1]  G. Groenewegen,et al.  Class II antigens on canine T lymphocytes. , 2008, Tissue antigens.

[2]  W. Bodmer,et al.  Monoclonal antibodies to HLA--DRw determinants. , 2008, Tissue antigens.

[3]  F. Galibert,et al.  An integrated linkage-radiation hybrid map of the canine genome , 2000, Mammalian Genome.

[4]  Sebastiaan Overeem,et al.  Hypocretin (orexin) deficiency in human narcolepsy , 2000, The Lancet.

[5]  J A Gerlach,et al.  Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: Second report of the ISAG DLA Nomenclature Committee. , 1999, Tissue antigens.

[6]  J A Gerlach,et al.  Nomenclature for factors of the dog major histocompatibility system (DLA), 1998. First report of the ISAG DLA Nomenclature Committee. International Society for Animals Genetics. , 1999, Tissue antigens.

[7]  Emmanuel Mignot,et al.  The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene , 1999, Cell.

[8]  Stephen H. Bell,et al.  Interbreed variation of DLA-DRB1, DQA1 alleles and haplotypes in the dog. , 1999, Veterinary immunology and immunopathology.

[9]  J. Siegel,et al.  Neuronal Degeneration in Canine Narcolepsy , 1999, The Journal of Neuroscience.

[10]  R. Houlston,et al.  Genetic susceptibility to gluten sensitive enteropathy in Irish setter dogs is not linked to the major histocompatibility complex. , 1998, Tissue antigens.

[11]  R. Storb,et al.  DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. , 1998, Tissue antigens.

[12]  H. Deeg,et al.  Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. , 1998, Blood.

[13]  E. Mignot,et al.  Genetic and familial aspects of narcolepsy , 1998, Neurology.

[14]  C. Guilleminault,et al.  HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. , 1997, Sleep.

[15]  E. Mignot,et al.  PHARMACOLOGICAL ASPECTS OF HUMAN AND CANINE NARCOLEPSY , 1997, Progress in Neurobiology.

[16]  P. Underhill,et al.  Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. , 1997, Tissue antigens.

[17]  R. Storb,et al.  Molecular analysis of the DLA DR region. , 1996, Tissue antigens.

[18]  E. Ostrander,et al.  Histocompatibility testing of dog families with highly polymorphic microsatellite markers. , 1996, Transplantation.

[19]  R. Storb,et al.  Molecular analysis and polymorphism of the DLA‐DQB genes , 1996 .

[20]  M. Aldrich,et al.  Major Histocompatibility Class II Molecules in the CNS: Increased Microglial Expression at the Onset of Narcolepsy in a Canine Model , 1996, The Journal of Neuroscience.

[21]  R. Storb,et al.  Nucleotide sequence and polymorphism analysis of canine DRA cDNA clones. , 1995, Tissue antigens.

[22]  P. Underhill,et al.  DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. , 1994, Sleep.

[23]  E. Bryant,et al.  USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING , 1994, Transplantation.

[24]  E. Mignot,et al.  Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  C. Guilleminault,et al.  DQB1-0602 (DQw1) is not present in most nonDR2 Caucasian narcoleptics. , 1992, Sleep.

[26]  M. Lovett,et al.  Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Beverley,et al.  Phenotypic changes associated with activation of CD45RA+ and CD45RO+ T cells. , 1990, Immunology.

[28]  W. Dement,et al.  Narcolepsy without unique MHC class II antigen association: studies in the canine model. , 1989, Human immunology.

[29]  R. Storb,et al.  Characterization of class II alpha genes and DLA-D region allelic associations in the dog. , 1988, Tissue antigens.

[30]  H. Mcdevitt,et al.  DNA sequence and characterization of human class II major histocompatibility complex beta chains from the DR1 haplotype. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[31]  F. Bach.  The HLA class II genes and products: the HLA-D region. , 1985, Immunology today.

[32]  R. Vaughan,et al.  GENETIC MARKERS IN NARCOLEPSY , 1984, The Lancet.

[33]  M. Satake,et al.  HLA antigens in Japanese patients with narcolepsy , 1984 .

[34]  M. Mitler,et al.  Canine model of narcolepsy: Genetic and developmental determinants , 1982, Experimental Neurology.

[35]  M. Mitler,et al.  Narcolepsy-cataplexy in a female dog. , 1974, Experimental neurology.

[36]  N. Morton.  Sequential tests for the detection of linkage. , 1955, American journal of human genetics.

[37]  R. Storb,et al.  Organization of the canine major histocompatibility complex: current perspectives. , 1999, The Journal of heredity.

[38]  N. Risch,et al.  HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. , 1998, Tissue antigens.

[39]  M. C. Ellis,et al.  HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy , 1997, Immunogenetics.

[40]  R. Storb,et al.  A simple restriction fragment-length polymorphism assay for MHC class II gene testing of dog families. , 1994, Transplantation.